

NIH/NIAID/DMID Partnerships Program Survey

Burden Disclosure: Public reporting burden for this collection of information is estimated to average 20 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA# 0925-0668. Do not return the completed form to this address.

Welcome!

You have been selected to participate in the external assessment of the NIH/NIAID/DMID Partnerships Program, which was initiated in 2002 to support product-focused research and development activities. Your participation in the survey is voluntary and you are free to skip any particular question you do not wish to answer for any reason.

You will receive no direct benefits from participating in the survey; however, your responses will provide critical data that will be incorporated into a summary report generated by an independent contractor for NIAID. All information obtained in the survey will be reported in aggregate. A designated NIAID External Partnerships Committee of senior academic and industrial scientists/developers will use the report to prepare a formal assessment of the program with recommendations for future directions and activities. There are no foreseeable risks of participating in this survey. The information you provide will be kept secure to the extent permitted by law.

The survey should take approximately 20 minutes to complete. If you have received more than one Partnerships award, please ensure that your responses are related to the award mentioned in your survey invitation. If you are unable to finish the survey in a single sitting, you will be able to resume the survey from the point where you stopped by selecting the link in the invitation email.

Thank you for taking the time to participate in this important program assessment. If you have any questions about the survey, please feel free to contact us.

Michael Schaefer at mschaefer@niaid.nih.gov Tina Parker at parkerti@niaid.nih.gov

If you are 18 years of age or older, understand the statements above and freely consent to participate in the survey, click on the "I Agree" link to begin the survey.

I Agree, launch survey.

I Do Not Agree





2%
Which of the following best describes the general product (countermeasure) focus of your project funded by the award referenced in your invitation email? (PLEASE SELECT ONLY ONE.)
Please use the 'Previous Question' button to navigate to earlier questions; do not use your browser's 'Back' button.
 Vaccine/Vaccine Technology/Adjuvant Therapeutic Diagnostic/Diagnostic Platform Technology
ImmunotherapeuticResearch Resource/Service/Process
○ Skip this Question
Next Question



			4%
What was the primary pathogen targeted	in the project?		
Skip this Question			



	6%	
If the Partnerships program was not available, would the project funded by the referenced award pursued?	still have been	
○ No ● Yes		
Not Sure/Don't KnowSkip this Question		
Previous Question Next Question		



	8%
Overall, how important has Partnerships support been, or how important will it be, in research and candidate product, process, or service? (PLEASE SELECT ONLY ONE.)	d development of this
 Very Important Important Somewhat Important Not Important 	
Skip this Question Previous Question Next Question	



	10%
Was there financial support from other sources for the project?	
○ No ● Yes	
⊎ INO ⊎ TeS	
Not Sure/Don't Know	
Skip this Question	
Previous Question Next Question	
THOSE QUOCHOT	



	12%
Please identify the source(s) of parallel support:	
Skip this Question Previous Question Next Question	



	14%
Which one of the following $\underline{\text{best}}$ characterizes the product, process, or service that was planned un (PLEASE SELECT ONLY ONE.)	nder this project?
 A totally new product, process, or service A new use for an existing product, process, or service An improvement to an existing product, process, or service A combination of products, processes, or services Other 	
Skip this Question	
Previous Question Next Question	



	16%	
Specify what else best characterizes the product, process, or service that was planned:		
Skip this Question		
Previous Question Next Question		



	18%
Did Partnerships support provide technical validation (e.g., scientific concept vetted, p manufacturability)?	roof of concept,
○ No ● Yes	
Not Sure/Don't KnowSkip this Question	
Previous Question Next Question	



	20%
Did Partnerships support provide data that led to acquisition of follow-on fun	ding?
○ No ● Yes	
Not Sure/Don't KnowSkip this Question	
Previous Question Next Question	



	22%
None identify the course(a) of fallow on five direct	<u> </u>
Please identify the source(s) of follow-on funding:	
Skip this Question	
Previous Question Next Question	



	25%
Did Partnerships support contribute to publications?	
○ No ● Yes	
Not Sure/Don't Know	
Skip this Question	
Previous Question Next Question	



	27%
Please provide citation(s):	
Skip this Question	
Skip this Question	
Previous Question Next Question	



	29%
Did you develop an animal model, assay, reagent or product used by other investigator(s)?	
○ No ● Yes	
Not Sure/Don't KnowSkip this Question	
Previous Question Next Question	



	31%
Please identify the animal model, assay, reagent or product developed:	
Skip this Question	
Previous Question Next Question	



	33%
	<u> </u>
Please describe the purpose of the animal model, assay, reagent or product:	
Skip this Question	
Skip tills Question	
Previous Question Next Question	



	35%
Did the studies conducted with Partnerships support influence the decision to move forward?	
No ○ Yes	
Not Sure/Don't KnowSkip this Question	
Previous Question Next Question	



	37%
	37%
Please describe how the studies influenced your decision not to move forwa	ard:
Le la	
Skip this Question	
Previous Question Next Question	



	39%
	39%
lease describe the most significant outcome of the supported research:	
Skip this Question	
Skip this Question	



	41%
Did the projects involve a candidate product (as evidenced by proof of principle)?	
Examples of a candidate product include countermeasures against NIAID Category A, B, or C prior as a vaccine, therapeutic, immunotherapeutic, diagnostic, adjuvant or related platform technology	
○ No ● Yes	
Skip this Question	
Previous Question Next Question	



	43%
Did Partnerships support advance a candidate product along the product development pathway?	
○ No ● Yes	
Not Sure/Don't KnowSkip this Question	
Previous Question Next Question	



	45%
What was the developmental status of the candidate product <u>prior to the award period</u> ? (PLEASE	SELECT ONLY ONE.)
 Basic Research Early Translational (e.g., assay development, screening, target identification) Translational (e.g., efficacy testing, model development, medicinal chemistry) Preclinical Activities (e.g., safety, tox, production) Pre-Investigational New Drug (Pre-IND) Investigational New Drug (IND) 	
Skip this Question	
Previous Question Next Question	



	47%
What was/is the developmental status of the candidate product <u>at the end of the award period</u> ? (IONE.)	PLEASE SELECT ONLY
 Basic Research Early Translational (e.g., assay development, screening, target identification) Translational (e.g., efficacy testing, model development, medicinal chemistry) Preclinical Activities (e.g., safety, tox, production) Pre-Investigational New Drug (Pre-IND) Investigational New Drug (IND) 	
Skip this Question	
Previous Question Next Question	



	50%
Was the candidate product acquired by, or licensed to, a partner/industry?	
○ No ● Yes	
Not Sure/Don't KnowSkip this Question	
Previous Question Next Question	



	52%
Was there a transfer of technology/candidate product to other investigator(s)?	
○ No ● Yes	
Not Sure/Don't KnowSkip this Question	
Previous Question Next Question	



	54%
	34-70
Did Partnerships support contribute to pending intellectual property rights application?	
○ No ● Yes	
Not Sure/Don't Know	
Skip this Question	
Previous Question Next Question	



	56%
Did Partnerships support contribute to acquisition of intellectual property rights?	
○ No ○ Yes	
Not Sure/Don't Know	
Skip this Question	
Previous Question Next Question	



	58%
Did Partnerships support contribute to FDA submission?	
○ No ○ Yes	
Not Sure/Don't KnowSkip this Question	
Previous Question Next Question	



	60%
Please identify what type of submission was made:	
rease identity what type of submission was made.	
Skip this Question	
Previous Question Next Question	



	62%	
Please provide the <u>current</u> status of the submission: (PLEASE SELECT ONLY ONE.)		
Under FDA review		
Product has FDA approval		
Product is on clinical-hold		
Other		
Skip this Question		
Previous Question Next Question		



	64%
lease specify other current status of the submission:	
Skip this Question	
Previous Question Next Question	



	66%
	00 /0
Did Partnerships support lead to a label change for new indication?	
○ No ● Yes	
Not Sure /Don't Know	
Not Sure/Don't KnowSkip this Question	
Previous Question Next Question	



68%
What is the current status of the candidate product developed by the referenced Partnerships award? (PLEASE SELECT ONLY ONE.)
 Under development Commercialization stage In use by target population Discontinued Other
Skip this Question
Previous Question Next Question



		70%
losso specify the other	status of the candidate product:	
rease specify the other	status of the candidate product.	
Skip this Question		
Previous Question	Next Question	



	72%
Did the reasons for discontinuing development of the candidate product include any of the following ALL THAT APPLY.)	ıg? (PL
☐ Idea failed due to insufficient efficacy	
Idea failed due to inadequate safety margin	
☐ Market demand too small	
Level of risk too high	
□ Not enough funding	
Company shifted priorities	
Principal investigator left	
□ No FDA approval	
Licensed to another company	
 Product, process, or service not competitive 	
Other	
Skip this Question	
Previous Question Next Question	



		750/
		75%
Please specify other rea	ason for discontinuing development of the candidate produ	ıct·
icase specify other rec	bon for absorbing development of the candidate produ	
Skip this Question		
Skip this Question		



	77%
Has the PI/company obtained any other NIH awards, in addition to the referenced award services that are related to this project? (The awards may have different principal invest come before or after the referenced award or from different NIH agencies.)	
○ No ○ Yes	
Not Sure/Don't KnowSkip this Question	
Previous Question Next Question	



	79%
Please list the NIH institute(s) from which the PI/company has obtained any other NIH may have different principal investigators, and they may have come before or after the	
different NIH agencies.	e referenced award of from
Skip this Question	
Previous Question Next Question	



	81%
Did you have an industrial partner for your Partnerships <u>during the award period</u> ?	
○ No ○ Yes	
Skip this Question	
Previous Question Next Question	



83%
Which of the following best describes this company's (or industrial partner's) <u>major</u> field of business? (PLEASE SELECT ONLY ONE.)
 Biotechnology Pharmaceuticals Diagnostics Non-Profit Healthcare
Skip this Question
Previous Question Next Question



	85%
What is the current status of the company (or industrial partner)? (PLEASE SELECT ONLY ONE.)	
 Actively engaged in the same business Merged with another company Sold Closed Other 	
Skip this Question Previous Question Next Question	



	87%
Please specify other current status of the company (or industrial partner):	
Skip this Question	
Previous Question Next Question	



89%		
Thinking now just about the referenced award, how satisfied were you with your experiences going through the Partnerships application, review, and award process.		
How satisfied were you with obtaining information about the Partnerships program?		
 Very dissatisfied Mostly dissatisfied Mixed Mostly satisfied Very satisfied 		
Skip this Question Not Applicable		
Previous Question Next Question		



	91%
How satisfied were you with instructions for preparing applications?	
 Very dissatisfied Mostly dissatisfied Mixed Mostly satisfied Very satisfied 	
Skip this Question Not Applicable Previous Question Next Question	



	93%
How satisfied were you with the review process ?	
 Very dissatisfied Mostly dissatisfied Mixed Mostly satisfied Very satisfied 	
Skip this Question Not Applicable Previous Question Next Question	



	95%
How satisfied were you with the award process ?	
 Very dissatisfied Mostly dissatisfied Mixed Mostly satisfied Very satisfied 	
Skip this QuestionNot Applicable	
Previous Question Next Question	



	97%
How satisfied were you with the post-award administration ?	
 Very dissatisfied Mostly dissatisfied Mixed Mostly satisfied Very satisfied 	
Skip this Question Not Applicable	
Previous Question Next Question	



100%
Please provide any additional information about the Partnerships application, review, and award process that you think may be helpful to us.
After entering your response, select "Submit Survey" to complete.
Skip this Question Previous Question Submit Survey



NIH/NIAID/DMID Partnerships Program Survey

Survey Complete!

Thank you for taking the time to participate in this important program assessment.

Michael Schaefer at mschaefer@niaid.nih.gov Or Tina Parker at parkerti@niaid.nih.gov



NIH/NIAID/DMID Partnerships Program Survey

We are sorry that you have decided not to participate in our assessment of the NIH/NIAID/DMID Partnerships program. If you change your mind, you can select the link in the invitation email to complete the survey at a later date.

If you would like to complete the survey via telephone or paper survey, or if you would like to share anything about your experience with the Partnerships program outside of the survey, please feel free to contact us at:

Michael Schaefer at mschaefer@niaid.nih.gov Tina Parker at parkerti@niaid.nih.gov





NIH/NIAID/DMID Partnerships Program Survey

Burden Disclosure: Public reporting burden for this collection of information is estimated to average 20 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA# 0925-0668. Do not return the completed form to this address.

Click here to resume the NIH/NIAID/DMID Partnerships Program Survey.

Remember, your participation in this survey is voluntary and you are free to skip any particular question you do not wish to answer for any reason. You will receive no direct benefits from participating in the survey; however, your responses will provide critical data that will be incorporated into a summary report generated by an independent contractor for NIAID. All information obtained in the survey will be reported in aggregate. A designated NIAID External Partnerships Committee of senior academic and industrial scientists/developers will use the report to prepare a formal assessment of the program with recommendations for future directions and activities. There are no foreseeable risks of participating in this survey.

If you have any questions about the survey, please feel free to contact us. The information you provide will be kept secure to the extent permitted by law.

Michael Schaefer at mschaefer@niaid.nih.gov Tina Parker at parkerti@niaid.nih.gov

